Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Fan, Chunpeng" or (type exact bookEditor and editor="Fan, Chunpeng")

Add to list
- Journal Article
- A1
- open access
Dupilumab in CRSwNP : responder analysis using clinically meaningful efficacy outcome thresholds

Chien‐Chia Chuang, Isabelle Guillemin, Claus Bachert (UGent) , Stella E. Lee, Peter Hellings (UGent) , Wytske J. Fokkens, Nicolas Duverger, Chunpeng Fan, Nadia Daizadeh, Nikhil Amin, et al.

(2022) LARYNGOSCOPE. 132(2). p.259-264
Add to list
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP

Claus Bachert (UGent) , S James Zinreich, Peter Hellings (UGent) , Joaquim Mullol, Daniel L Hamilos, Philippe Gevaert (UGent) , Robert M Naclerio, Nikhil Amin, Vikay N Joish, Chunpeng Fan, et al.

(2020) RHINOLOGY. 58(1). p.10-17
Add to list
Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis

Claus Bachert (UGent) , Peter Hellings (UGent) , Joaquim Mullol, Daniel L Hamilos, Philippe Gevaert (UGent) , Robert M Naclerio, Vijay N Joish, Jingdong Chao, Leda P Mannent, Nikhil Amin, et al.

(2020) ALLERGY. 75(1). p.148-157
Add to list
- Journal Article
- A1
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD

Tanya M Laidlaw, Joaquim Mullol, Chunpeng Fan, Donghui Zhang, Nikhil Amin, Asif H. Khan (UGent) , Jingdong Chao and Leda P Mannent

(2019) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE. 7(7). p.2462-2465
Add to list
- Journal Article
- A1
- open access
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis

Karin Jonstam, Brian N Swanson, Leda P Mannent, Lars-Olaf Cardell, Nian Tian, Ying Wang, Donghui Zhang, Chunpeng Fan, Gabriële Holtappels (UGent) , Jennifer D Hamilton, et al.

(2019) ALLERGY. 74(4). p.743-752
Add to list
Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps : results from the randomized phase 3 sinus-24 study

Joseph K Han, Claus Bachert (UGent) , Martin Desrosiers, Tanya M Laidlaw, Claire Hopkins, Wytske J Fokkens, Pierluigi Paggiaro, Seong Ho Cho, Heidi Olze, Leon S Greos, et al.

(2019) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 143(2, suppl.). p.AB422-AB422
Add to list
- Conference Paper
- C3
- open access
A randomized phase 3 study, SINUS-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps

Claus Bachert (UGent) , Martin Desrosiers, Joaquim Mullol, Peter Hellings (UGent) , Anders Cervin, Lawrence Sher, John V Bosso, Stella E Lee, Jorge F Maspero, Shigeharu Fujieda, et al.

(2019) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 143(2, suppl.). p.AB433-AB433
Add to list
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) : results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Claus Bachert (UGent) , Joseph K Han, Martin Desrosiers, Peter W Hellings, Nikhil Amin, Stella E Lee, Joaquim Mullol, Leon S Greos, John V Bosso, Tanya M Laidlaw, et al.

(2019) LANCET. 394(10209). p.1638-1650
Add to list
Atopic comorbidities and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) who failed intranasal corticosteroids

Claus Bachert (UGent) , Peter W Hellings, Joaquim Mullol, Robert M Naclerio, Daniel L Hamilos, Philippe Gevaert (UGent) , Dongui Zhang, Asif Khan, Chunpeng Fan, Nikhil Amin, et al.

(2018) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 141(2, suppl.). p.AB90-AB90
Add to list
- Conference Paper
- C3
Dupilumab improves sense of smell and reduces anosmia among patients with nasal polyposis and chronic sinusitis : results from a phase 2a trial

Robert M. Naclerio, Daniel L. Hamilos, Berrylin J. Ferguson, Claus Bachert (UGent) , Peter W. Hellings, Joaquim Mullol, Philippe Gevaert (UGent) , Donghui Zhang, Asif H. Khan (UGent) , Chunpeng Fan, et al.

(2017) JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 139(2). p.AB90-AB90
Add to list
- Conference Paper
- C3
Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma : results from a phase 2a trial

Claus Bachert (UGent) , Peter Hellings (UGent) , Joaquim Mullol, Daniel Hamilos, Robert Naclerio, Vijay N Joish, Leda Mannent, Robert E Evans, Annette Grabher, Adeline Abbe, et al.

(2016) EUROPEAN RESPIRATORY JOURNAL. In European Respiratory Journal 48(Supplement 60).

Academic Bibliography

Dupilumab in CRSwNP : responder analysis using clinically meaningful efficacy outcome thresholds

Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP

Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis

Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD

Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis

Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps : results from the randomized phase 3 sinus-24 study

A randomized phase 3 study, SINUS-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) : results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Atopic comorbidities and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) who failed intranasal corticosteroids

Dupilumab improves sense of smell and reduces anosmia among patients with nasal polyposis and chronic sinusitis : results from a phase 2a trial

Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma : results from a phase 2a trial

Contents

Support

Contact